ClinicalTrials.gg
CompletedNCT05542342SITISVEALUpdated Jun 1, 2026Results posted

Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

A Phase 2 interventional study of Tislelizumab and Sitravatinib in Uveal Melanoma With Liver Metastases, sponsored by Grupo Español Multidisciplinar de Melanoma. Completed at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Grupo Español Multidisciplinar de Melanoma · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Melanoma by Grupo Español Multidisciplinar de Melanoma — 2 open to participants now, 4 under way, none of them phase 3. Melanoma · Grupo Español Multidisciplinar de Melanoma.

Started
2022
the only one that year
Phase 2
8 of 11
2 open now
Registered
8th of 11
by date

Among the 11 studies in Melanoma by Grupo Español Multidisciplinar de Melanoma, this one is the only one that started in 2022, is one of 8 in phase 2, and was the 8th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 11 studies in Melanoma by Grupo Español Multidisciplinar de Melanoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Melanoma by Grupo Español Multidisciplinar de Melanoma, or all of them as a file.
02

Study summary

SITISVEAL stablish the hypothesis that treatment with Tislelizumab + Sitravatinib will increase the Objective Response Rate in patients with Metastatic Uveal Melanoma with liver metastases, compared with the current standard of care.

This is a non-randomized, single arm, multicenter, phase II study of Sitravatinib in combination with Tislelizumab in subjects with metastatic uveal melanoma and liver metastases. After informed consent is obtained, subjects will enter in the Screening phase to assess eligibility criteria and perform a mandatory tumor biopsy. Upon meeting criteria, eligible subjects will be entered into the Treatment phase. Patients will receive Sitravatinib 100 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until progression of disease, unacceptable toxicity, death, or consent withdrawal, whichever occurs first. Treatment may be continued after progression according to physician criteria (with previous consultation with Coordinating investigator) until patients no longer receive clinical benefit.

Read the detailed description

This was a non-randomised, single-arm, multicentre, phase II study of sitravatinib in combination with tislelizumab in patients with metastatic uveal melanoma and liver metastases. This study was divided into 3 phases: Screening, Treatment, and Follow-up. After informed consent was obtained, the subjects entered the screening phase to assess eligibility criteria and performed a mandatory tumour biopsy. Upon meeting these criteria, eligible subjects were included in the treatment phase. Patients received sitravatinib 100 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, death, or consent withdrawal, whichever occurred first. Treatment could be continued after progression according to physician criteria (with previous consultation with Coordinating investigator) until patients no longer received clinical benefit.

Subjects were examined weekly by investigators during the first two cycles to closely follow up diarrhoea and hypertension that could be observed due to treatment with sitravatinib. Patients could be visited at least every three weeks thereafter, and every time the Principal Investigator deemed necessary. A new tumour biopsy was mandatory and was performed before the 3rd dose of tislelizumab.

Subjects, either on treatment of after they were no longer receiving sitravatinib and tislelizumab because of unacceptable toxicity or due to investigator judgement, underwent radiological evaluations of the tumour every 6 weeks during the first 12 months (48 weeks) after treatment initiation, and then every 12 weeks until disease progression. Subjects who were no longer receiving sitravatinib and tislelizumab because of disease progression entered the long-term overall survival follow-up until death or until the end of the study (whatever happened before). Subjects who had switched to alternative treatment without disease progression received a formal follow-up with imaging tests until progression, and after progression, long-term follow-up to record the date of death.

03

Conditions studied

  • Uveal Melanoma With Liver Metastases

Browse trials for

Keywords

  • melanoma
  • uveal
  • liver metastases
  • immune checkpoint inhibitors
  • targeted therapies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have confirmed uveal melanoma with not eligible for curative therapy.
  2. Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral computed tomography scan, magnetic resonance imaging, or calipers by clinical exam. Patients must have at least 1 biopsiable liver metastasis.
  3. Patients who are human leukocytes antigen (HLA)-A02:01 positive can have received one prior therapy with Tebentafusp for metastatic disease.
  4. Patients must be 18 years of age or older at time of study entry.
  5. Performance Status 0-1.
  6. Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations not performed according to normal practice. Patients must consent for liver metastasis donation at day 0 and day +42 since treatment initiation.
  7. Adequate normal organ and marrow function as defined below:

    1. ≥9.0 g/dL
    2. >1.5 x 109/L (> 1500 per mm3)
    3. count ≥ 100 x 109/L (>75,000 per mm3)
    4. Serum ≤1.5 x institutional (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with Coordinating Investigator
    5. Both and alanine aminotransferase must be \<5 x ULN.
    6. ⩾40 ml/min calculated by Cockcroft-Gault or another validated method
    7. Urine protein:creatinine ratio (UPC) ≤1 or ≤2+ proteinuria on 2 consecutive dipsticks taken no less than 1 week apart
    8. Subjects with 2+ proteinuria on dipstick must also have UPC \< 0.5 on 2 consecutive samples.
  8. Females of must be willing to use a highly effective method of for the duration of the study, and for 6 months after the last dose of tislelizumab and/or sitravatinib, and have a negative urine or serum pregnancy test ≤7 days before first administration of tislelizumab and sitravatinib. Women will be considered if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    1. Amenorrheic for ≥1 year in the absence of chemotherapy and/or hormonal treatments
    2. Luteinizing hormone and/or follicle stimulating hormone and/or estradiol levels in the post-menopausal range
    3. Radiation induced oophorectomy with last menses >1 year ago
    4. Chemotherapy induced menopause with >1 year interval since last menses
    5. Surgical sterilization (bilateral oophorectomy or hysterectomy)
    6. Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)
    7. Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  9. For both male and female patients/partners: Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 6 months after the last dose of tislelizumab and/or sitravatinib. A sterile male is defined as:

    1. One for whom azoospermia has been previously demonstrated in a semen sample examination as definitive evidence of infertility.
    2. Males with known "low sperm counts" (consistent with "sub-fertility") are not to be considered sterile for purposes of this study.
  10. Patient is willing and able to comply with the protocol procedures for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
  11. Must have a of at least 12 weeks
  12. Subjects must be able to swallow and retain oral medications and be without gastrointestinal illnesses that would preclude absorption of Sitravatinib.
  13. Adequately controlled blood pressure:

Systolic blood pressure ≤140 mmHg and diastolic blood pressure ≤90 mmHg in the presence or absence of a stable regimen of antihypertensive therapy.

Exclusion criteria

Exclusion Criteria:

  1. Patients with concomitant other than non-melanoma skin cancer, or superficial bladder cancer controlled with local treatment.
  2. Previous treatment with targeted therapies and/or anti-angiogenic agents such as VEGFR, mitogen activated protein kinase (MAPK) - extracellular signal-regulated kinase (ERK), BRAF, ERK inhibitors, with the exception of tebentafusp.
  3. Previous treatment with , either anti-programmed dead 1 (PD1)/PD-L1 (including tislelizumab), anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), or other treatments.
  4. Presence of brain or unless previously treated, off at least 2 weeks, and considered stable. Patients with untreated central nervous system (CNS) and/or carcinomatous meningitis identified either on the baseline brain imaging []) obtained during the screening period or identified prior to signing the ICF. Patients whose have been treated may participate provided they show radiographic stability (defined as 2 brain images, both of which are obtained after treatment to the brain metastases. These imaging scans should both be obtained at least four weeks apart and show no evidence of intracranial progression). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable either, without the use of steroids, or are stable on a steroid dose of ≤10mg/day of prednisone or its equivalent and anticonvulsants, for at least 14 days prior to the start of treatment. Brain metastases will not be recorded as RECIST Target Lesions at baseline.
  5. Patients weighing \<30kg will be excluded from enrollment.
  6. Participation in another clinical study with an product during the last 4 weeks.
  7. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
  8. Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies) ≤28 days prior to the first dose of study drug. If sufficient time has not occurred due to the schedule or Pharmacokinetic properties of an agent, a longer wash-out period will be required, as agreed by Sponsor designated Coordinating Investigator and Principal Investigator.
  9. Any unresolved toxicity Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria

    1. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Coordinating Investigator.
    2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with Tislelizumab may be included only after consultation with the Coordinating Investigator.
    3. Known toxicity on prior checkpoint inhibitor treatment:

    I) Grade ≥ 3 immune-related adverse event (AE) related to checkpoint inhibitors.

    II) Grade 2 immune-related AE associated with checkpoint inhibitor unless the AE resolved or was well III) controlled by withholding the checkpoint inhibitor and/or treatment with steroids, with the exception of prior colitis, myocarditis, and pneumonitis, which are exclusionary.

    CNS or ocular AE of any grade related to checkpoint inhibitors. Note: Patients with a prior endocrine AE are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.

  10. Any concurrent chemotherapy, investigational medicinal product (IMP), biologic, or hormonal therapy for cancer treatment different to Sitravatinib and/or Tislelizumab. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
  11. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
  12. Major surgery within a minimum of 4 weeks prior to inclusion; patients must have recovered from any effects of any major surgery prior to inclusion. Note: Local surgery of isolated lesions for palliative intent and minor surgeries performed to obtain biological material for the study (i.e. liver ) are acceptable.
  13. History of allogeneic organ transplantation.
  14. Active or prior documented or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

    1. Patients with vitiligo or alopecia
    2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
    3. Any chronic skin condition that does not require systemic therapy
    4. Patients without active disease in the last 5 years may be included but only after consultation with the Coordinating Investigator
    5. Patients with celiac disease controlled by diet alone
  15. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled/malignant hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, compromise Sitravatinib absorption, substantially increase risk of incurring AEs or compromise the ability of the patient to give written .
  16. History of another primary malignancy except for:

    1. Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IMP and of low potential risk for recurrence
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    3. Adequately treated carcinoma in situ without evidence of disease
  17. History of active primary immunodeficiency.
  18. Active infection including tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), (known positive hepatitis B virus surface antigen (HBsAg) result), , or (positive HIV 1/2 antibodies). Patients with a past or resolved hepatitis B virus infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibodies are eligible only if polymerase chain reaction is negative for HCV RNA.
  19. Current or prior use of medication within 14 days before the first dose of Tislelizumab. The following are exceptions to this criterion:

    1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
    2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    3. Steroids as premedication for reactions (e.g., CT scan premedication)
  20. Receipt of within 30 days prior to the first dose of IMP. Note: Patients, if enrolled, should not receive live vaccines whilst receiving IMP and up to 30 days after the last dose of IMP.
  21. Female patients who are pregnant (confirmed with positive pregnancy test) or breastfeeding or male or female patients of who are not willing to employ effective from screening to 6 months after the last dose of tislelizumab and/or Sitravatinib therapy.
  22. History of severe allergic reaction attributed to sitravatinib or a similar VEGFR inhibitor or known hypersensitivity to any component of sitravatinib dose composition
  23. Known allergy or hypersensitivity to tislelizumab or sitravatinib or any of the .
  24. History of gastrointestinal perforation. Subjects with a history of abdominal fistula will be eligible if:

    1. the fistula has been surgically repaired,
    2. there is no evidence of fistula for at least 6 months prior to inclusion, and
    3. the subject is deemed to be at low risk of recurrent fistula in the opinion of the Investigator.
  25. History of intra-abdominal abscess within 3 months prior to inclusion
  26. signs and/or symptoms of bowel obstruction within 3 months prior to inclusion
  27. Resting with clinically significant abnormal findings. i.e. Mean corrected for heart rate using Fridericia's formula ≥470 ms calculated from 3 electrocardiograms (within 15 minutes at 5 minutes apart).
  28. Subjects with any one or more of the following:

    1. History of myocardial infarction within 6 months prior to inclusion; patients with a history of myocardial infarction within 6 to 12 months prior to inclusion may be allowed following assessment
    2. Unstable angina within 6 months prior to inclusion
    3. Known significant cardiac disease ( classification of III or IV).
    4. Concomitant medication known to cause prolonged QT which cannot be discontinued or changed to a different medication prior to enrollment
  29. \< lower limit of normal (LLN) per institutional guidelines, or \<55%, if threshold for normal is not otherwise specified by institutional guidelines, for patients with the following risk factors:

    1. Prior or planned treatment with anthracyclines (ie, PLD)
    2. Prior treatment with trastuzumab
    3. Prior central thoracic radiation therapy (RT), including exposure of heart to therapeutic doses of ionizing RT
    4. History of myocardial infarction within 6 to 12 months prior to inclusion
    5. Prior history of other significant impaired cardiac function.
  30. History of stroke or within 6 months prior to inclusion.
  31. History of significant hemorrhage within 4 weeks of first dose date.
  32. Patients with:

    1. With uncontrolled diabetes or > Grade 1 laboratory test abnormalities in potassium, sodium, or corrected calcium despite standard medical management or ≥ Grade 3 hypoalbuminemia ≤ 14 days before
    2. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence ≤ 14 days after intervention)
    3. History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, or acute lung diseases. Patients with significantly impaired pulmonary function, or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening
  33. Evidence of any other disease, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that puts the subject at high risk for treatment-related complication.
  34. Prior enrollment or treatment in a previous Tislelizumab and/or Sitravatinib clinical study regardless of treatment arm assignment.
  35. Any serious medical condition or psychiatric illness that would interfere in understanding of the informed consent form.
Terms in these criteria, in plain language(41)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Experimental arm

    Patients with uveal melanoma with liver metastasis will receive sitravatinib 100 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until progression of disease, unacceptable toxicity, death, or consent withdrawal, whichever occurs first. Treatment may be continued after progression according to physician criteria (with previous consultation with Coordinating investigator) until patients no longer receive clinical benefit.

    Drug: Tislelizumab · Drug: Sitravatinib

Interventions

  • 200 mg intravenously once every 3 weeks

  • 100 mg orally once daily

    Also known as: Sitravatinib Malate

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of patients with at least one complete response (CR) or partial response (PR) that is confirmed at least 4 weeks later according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.

    Time frame: Throughout the study period, approximately 1 year per patient

Secondary outcomes

  1. Progression-Free Survival (PFS)

    For this protocol, PFS is defined as the time from the first dose of study treatment until objective tumor progression according to RECIST 1.1 or death, whichever occurs first.

    Time frame: Throughout the study period, approximately 1 year per patient

  2. Overall Survival (OS)

    Overall Survival is defined as the time from the first dose of study treatment until death from any cause. Those patients that do not present a death event or are lost to follow up will be censored at the date of the last contact.

    Time frame: Throughout the study period, approximately 1 year per patient

07

Results

Posted Jun 1, 2026
Limitations and caveats
The small sample size limited the analysis of prognostic factors, such as the risk of death in patients with high alkaline phosphatase levels at baseline. It would be helpful if the analysis of prognostic factors is included in future studies conducted on patients with metastatic uveal melanoma (mUM). This limitation also makes it difficult to draw conclusions. However, the small sample size is strongly related to the very low prevalence of mUM.

Participant flow

Participant flow — Overall Study
MilestoneExperimental Arm
Started16
Completed2
Not completed14

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR is defined as the proportion of patients with at least one complete response (CR) or partial response (PR) that is confirmed at least 4 weeks later according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.

Time frame:
Throughout the study period, approximately 1 year per patient
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsExperimental Arm
Objective Response Rate (ORR)3
SecondaryProgression-Free Survival (PFS)

For this protocol, PFS is defined as the time from the first dose of study treatment until objective tumor progression according to RECIST 1.1 or death, whichever occurs first.

Time frame:
Throughout the study period, approximately 1 year per patient
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsExperimental Arm
Progression-Free Survival (PFS)7.7 (5.6 to NA)
SecondaryOverall Survival (OS)

Overall Survival is defined as the time from the first dose of study treatment until death from any cause. Those patients that do not present a death event or are lost to follow up will be censored at the date of the last contact.

Time frame:
Throughout the study period, approximately 1 year per patient
Reported as:
Median · months
Overall Survival (OS)
monthsExperimental Arm
Overall Survival (OS)15.9 (11.6 to NA)

Adverse events

Collected over 32 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Arm1/16 (6.3%)8/16 (50%)16/16 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventExperimental Arm
DiarrheaGastrointestinal disorders2/16
PneumonitisRespiratory, thoracic and mediastinal disorders1/16
Pulmonary embolismVascular disorders1/16
HypertensionVascular disorders1/16
PruritusSkin and subcutaneous tissue disorders1/16
Application site rashGeneral disorders1/16
Septic shockVascular disorders1/16
Enterocolitis infectiousInfections and infestations1/16
HypertransaminasaemiaHepatobiliary disorders1/16
Nervous system disorderNervous system disorders1/16
Most frequent other events
Showing 10 of 53
Most frequent other events
EventExperimental Arm
AstheniaGeneral disorders15/16
DiarrheaGastrointestinal disorders15/16
Decreased appetiteMetabolism and nutrition disorders11/16
HypertensionVascular disorders10/16
NauseaGastrointestinal disorders7/16
Accelerated hypertensionVascular disorders7/16
Alanine aminotransferase increasedInvestigations7/16
DysphoniaNervous system disorders6/16
DysgeusiaNervous system disorders6/16
Abdominal pain upperGastrointestinal disorders5/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Experimental Arm
Median63 (49 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Arm
Female8
Male8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Experimental Arm
Caucasian16
Region of Enrollment
Region of Enrollment(participants)Experimental Arm
Spain16
Weight
Weight(kg)Experimental Arm
Median71 (52.8 to 105.8)
Systolic Blood Pressure
Systolic Blood Pressure(mmHg)Experimental Arm
Median134.5 (105 to 155)
Diastolic Blood Pressure
Diastolic Blood Pressure(mmHg)Experimental Arm
Median79.5 (57 to 94)
Temperature
Temperature(ºC)Experimental Arm
Median36.3 (35 to 36.6)

9 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • Hospital Universitario Virgen de la Macarena
    Seville, Andalusia 41009, Spain
  • Institut Catala Oncologia (ICO) L´Hospitalet
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
  • Hospital Universitario la Paz
    Madrid, 28046, Spain
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Dec 2023, 15 months.

Results were first posted in Jun 2026, 2 years 5 months after primary completion.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's 15 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2022
First posted
Sep 15, 2022
StartActual
Sep 23, 2022
Primary completionActual
Dec 31, 2023
CompletionActual
May 6, 2025
Results first posted
Jun 1, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05542342
Lead sponsor
Grupo Español Multidisciplinar de Melanoma
Responsible party
Sponsor
First posted
Sep 15, 2022
Start date
Sep 23, 2022
Primary completion
Dec 31, 2023
Completion
May 6, 2025
Results posted
Jun 1, 2026
Last update
Jun 1, 2026

Study contacts

Josep Maria Piulats, M.D. Ph.D.
study chair · ICO L´Hospitalet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Sitravatinib

Start the discussion